antibody

Anti-Human Platelet Factor 4 (requires heparin for binding),Purified (Clone: KKO) (Mouse IgG2b)

MBS520552

0.2 mg

385 USD

monoclonal

mouse

nonconjugated

KKO

western blot, ELISA, enzyme immunoassay

Antibody

Anti-Human Platelet Factor 4 (requires heparin for binding),Purified (Clone: KKO) (Mouse IgG2b)

Platelet Factor 4

Platelet Factor 4 (requires heparin for binding),Purified (Clone: KKO) (Mouse IgG2b); Anti-Human Platelet Factor IV/Heparin

platelet factor 4; Platelet factor 4 variant; platelet factor 4 variant; PF4alt; PF4var1; C-X-C motif chemokine 4; platelet factor 4, variant 1 (PF4-like); platelet factor 4 variant 1; C-X-C motif chemokine 4 variant; CXCL4L1; PF4alt; PF4var1

PF4V1; PF4V1; PF4A; CXCL4L1; CXCL4V1; PF4-ALT; SCYB4V1; CXCL4V1; SCYB4V1

PF4V_HUMAN

Monoclonal

Mouse IgG2bkappa

KKO

Mouse

Human

104

Platelet Factor 4 (requires heparin for binding) (This antibody is specific for Human Platelet Factor IV/heparin complexes)

Purified

1.0 mg/ml

Store at +4 degree C. For long term storage, aliquot and freeze unused portion at -20 degree C in volumes appropriate for single use. Avoid freeze thaw cycles.

ELISA (EIA), Western Blot (WB)

This antibody is suitable for use in ELISA and Western Blot

Immunogen: Human Factor IV purified from the supernatant of thrombin activated platelets.

Presentation: Purified IgG buffered in PBS and 0.02% NaN3. (Purified from ascitic fluid via Protein G Chromatography).

Platelet factor IV is a 70 aa protein released from the alpha granules of activated platelets. PF4 is synthesized by bone marrow megakaryocytes and stored in alpha granules as a non-covalent bound tetramer. Platelet factor IV binds with high affinity to heparin and plays a role in inflammation and wound repair. PF4 is a chemoattractant for neutrophils, monocytes and fibroblasts and has been reported to be an immunologic regulator that inhibits suppressor T-cell activity. Heparin-Induced Thrombocytopenia/Thrombosis (HIT/HITT) is a life-threatening complication that manifests itself in a small population of patients exposed to intravenous-heparin. It is characterized by the production of PF4/heparin auto-antibodies. These auto-antibodies bind the PF4/heparin complexes and subsequently bind the FcgammaIIa receptor on the platelets surface through their Fc region. This activates the platelets and can initiate clot formation. (clone KKO), unlike (clone RTO) which binds PF4 alone, is specific for PF4/heparin complexes and is seen to have similar binding properties as auto-antibodies found in HIT/HITT.

292390

AAA60067.1

P10720

11,553 Da

Cell Surface Interactions At The Vascular Wall Pathway (106062); Chemokine Signaling Pathway (99051); Chemokine Signaling Pathway (96864); Common Pathway (106060); Cytokine-cytokine Receptor Interaction Pathway (83051); Cytokine-cytokine Receptor Interaction Pathway (460); Formation Of Fibrin Clot (Clotting Cascade) Pathway (106057); Hemostasis Pathway (106028)

Function: Inhibitor of angiogenesis. Inhibitor of endothelial cell chemotaxis (in vitro). Ref.5. Subunit structure: Homotetramer. Ref.6. Subcellular location: Secreted. Post-translational modification: The N-terminal processed forms of platelet factor 4 variant seems to be produced by proteolytic cleavage. The most abundant form is Platelet factor 4 variant(5-74). Miscellaneous: Binding to heparin is much weaker than in the close homolog PF4/CXCL4. Sequence similarities: Belongs to the intercrine alpha (chemokine CxC) family. Mass spectrometry: Molecular mass is 8250.9 Da from positions 31 - 104. Determined by ESI. Platelet factor 4 variant. Ref.5Molecular mass is 7877.7 Da from positions 34 - 104. Determined by ESI. Platelet factor 4 variant(4-74). Ref.5Molecular mass is 7805.8 Da from positions 35 - 104. Determined by ESI. Platelet factor 4 variant(5-74). Ref.5Molecular mass is 7678.6 Da from positions 36 - 104. Determined by ESI. Platelet factor 4 variant(6-74). Ref.5

0.2 mg

385 USD